Mr. Roderick Matheson reports

MARVEL BIOSCIENCES SECURES ALBERTA INNOVATES FUNDING TO SUPPORT THE PHASE I TESTING OF MB-204

Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc., have secured non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support the phase I testing of its lead compound, MB-204.

The $600,000 AICE-funded project represents a significant contribution toward the overall cost of the phase I clinical trial of MB-204 and supports the advancement of the program into human trials. The AICE program is highly competitive and subject to rigorous peer review, providing strong third party validation of the scientific and commercial potential of MB-204.

"On behalf of Marvel Biosciences, we are very grateful to Alberta Innovates for recognizing the importance and potential of MB-204 as a novel approach to treating autism spectrum disorders (ASD) and related conditions," commented chief executive officer Rod Matheson. "This competitive, peer-reviewed funding reinforces growing confidence around MB-204, and its potential to address sociobehavioural symptoms through a differentiated mechanism."

In addition to this award, Marvel also recently received a grant from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for the development of a novel, small volume, liquid-based formulation of MB-204. This pediatric-friendly formulation is designed to improve patient compliance, particularly for individuals with difficulty swallowing (refer to press release dated Feb. 18, 2026).

Together, these funding milestones reflect increasing validation of Marvel's development strategy and the therapeutic potential of MB-204, at a critical inflection point as it transitions from preclinical innovation to clinical-stage execution. With capital secured and formulation development already under way, the company is advancing toward clinical-stage execution with strong operational momentum.

About Marvel Biosciences Corp.

Marvel Biosciences, through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Marvel's lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market.

Research shows that blocking the A2A receptor may help treat conditions such as autism, depression and Alzheimer's disease. Marvel is also exploring MB-204's potential in rare disorders such as Rett syndrome and Fragile X syndrome to provide new options for patients with few effective treatments.

We seek Safe Harbor.